Faculty of Law and School of Public Health, Health Law and Science Policy Group, University of Alberta, Edmonton AB T6G 2H5, Alberta, Canada.
Annu Rev Med. 2012;63:23-33. doi: 10.1146/annurev-med-062110-123753. Epub 2011 Sep 1.
Direct-to-consumer (DTC) genetic testing has attracted a great amount of attention from policy makers, the scientific community, professional groups, and the media. Although it is unclear what the public demand is for these services, there does appear to be public interest in personal genetic risk information. As a result, many commentators have raised a variety of social, ethical, and regulatory issues associated with this emerging industry, including privacy issues, ensuring that DTC companies provide accurate information about the risks and limitations of their services, the possible adverse impact of DTC genetic testing on healthcare systems, and concern about how individuals may interpret and react to genetic risk information.
直接面向消费者（DTC）的基因检测引起了政策制定者、科学界、专业团体和媒体的极大关注。尽管尚不清楚公众对这些服务的需求是什么，但公众似乎对个人遗传风险信息感兴趣。因此，许多评论员提出了与这一新兴产业相关的各种社会、伦理和监管问题，包括隐私问题、确保 DTC 公司提供有关其服务风险和局限性的准确信息、DTC 基因检测对医疗保健系统可能产生的不利影响，以及对个人如何解释和对遗传风险信息做出反应的担忧。
